Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Neurocrine (NBIX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Revolution Medicines (RVMD)
LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines today and set a price target of $144.00. The company’s shares closed last Thursday at $98.90.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $115.87, a 19.5% upside from current levels. In a report issued on January 15, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $136.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Neurocrine, with a price target of $174.00. The company’s shares closed last Thursday at $136.14.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $182.06, representing a 34.3% upside. In a report issued on January 15, TipRanks – xAI also upgraded the stock to Buy with a $149.00 price target.
